Article Menu
Need Help?
Article Versions Notes
Action | Date | Notes | Link |
---|---|---|---|
article pdf uploaded. | 3 October 2024 15:33 CEST | Version of Record | https://www.mdpi.com/2072-6694/16/19/3389/pdf |
Cite
Karci, E.; Bilici, A.; Bayram, B.; Celayir, M.; Ozyurt, N.; Uluc, B.O.; Eken, A.; Basaran, G.; Demirci, U.; Kemal, Y.; et al. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study. Cancers 2024, 16, 3389. https://doi.org/10.3390/cancers16193389
Karci E, Bilici A, Bayram B, Celayir M, Ozyurt N, Uluc BO, Eken A, Basaran G, Demirci U, Kemal Y, et al. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study. Cancers. 2024; 16(19):3389. https://doi.org/10.3390/cancers16193389
Chicago/Turabian StyleKarci, Ebru, Ahmet Bilici, Buket Bayram, Melisa Celayir, Neslihan Ozyurt, BaÅŸak Oyan Uluc, Aynur Eken, Gul Basaran, Umut Demirci, Yasemin Kemal, and et al. 2024. "Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study" Cancers 16, no. 19: 3389. https://doi.org/10.3390/cancers16193389